Immunity, inflammation and disease · 2025
Serum SERPINB3/4 in Moderate-to-Severe Prurigo Nodularis: A Potential Biomarker for Disease Severity and Eosinophil-Related Parameters.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Jiali, Zhang Kaoyuan, Liao Yan, Yang Chener, Ge Jingyao, Wu Chenchen, Yu Bo, Zhong Weilong, Shao Yong, Dou Xia
Аннотация
BACKGROUND: The available evidence increasingly indicates that SERPINB3/4 plays a pivotal role in the progression of inflammatory diseases and may serve as a valuable biomarker for atopic dermatitis and psoriasis. However, the expression of SERPINB3/4 in the serum of patients with moderate-to-severe prurigo nodularis (PN) remains poorly understood.
OBJECTIVE: To find a promising biomarker for monitoring the severity and activity of moderate-to-severe PN patients.
METHODS: A total of 41 patients with moderate-to-severe PN and 20 healthy subjects were included in the study. Enzyme-linked immunosorbent assay (ELISA) was performed to determine serum SERPINB3/4 expression. Cutaneous SERPINB3/4 expression was evaluated by immunohistochemistry (IHC). Serum SERPINB3/4 levels were correlated with PN disease severity and activity scores, hematological parameters, and systemic inflammatory markers.
RESULTS: SERPINB3/4 expression was found to be significantly increased in the serum and lesions of PN in comparison to healthy subjects. In patients with PN, the expression of serum SERPINB3/4 was significantly elevated in subjects with higher investigator global assessment (IGA) scores, while exhibiting a notable decline in patients with higher pruritus numeric rating scale (P-NRS) scores. Positive correlations were observed between serum SERPINB3/4 levels and peripheral eosinophil count, eosinophil ratio, and eosinophil-to-lymphocyte ratio (ELR) in patients with PN.
CONCLUSION: SERPINB3/4 expression was increased in PN sera and lesions. Serum SERPINB3/4 expression was positively correlated with PN severity and peripheral eosinophil-related parameters, suggesting its potential as a promising biomarker for PN.
OBJECTIVE: To find a promising biomarker for monitoring the severity and activity of moderate-to-severe PN patients.
METHODS: A total of 41 patients with moderate-to-severe PN and 20 healthy subjects were included in the study. Enzyme-linked immunosorbent assay (ELISA) was performed to determine serum SERPINB3/4 expression. Cutaneous SERPINB3/4 expression was evaluated by immunohistochemistry (IHC). Serum SERPINB3/4 levels were correlated with PN disease severity and activity scores, hematological parameters, and systemic inflammatory markers.
RESULTS: SERPINB3/4 expression was found to be significantly increased in the serum and lesions of PN in comparison to healthy subjects. In patients with PN, the expression of serum SERPINB3/4 was significantly elevated in subjects with higher investigator global assessment (IGA) scores, while exhibiting a notable decline in patients with higher pruritus numeric rating scale (P-NRS) scores. Positive correlations were observed between serum SERPINB3/4 levels and peripheral eosinophil count, eosinophil ratio, and eosinophil-to-lymphocyte ratio (ELR) in patients with PN.
CONCLUSION: SERPINB3/4 expression was increased in PN sera and lesions. Serum SERPINB3/4 expression was positively correlated with PN severity and peripheral eosinophil-related parameters, suggesting its potential as a promising biomarker for PN.